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http://dx.doi.org/10.1016/j.ccr.2012.08.017SUMMARYThymic Stromal Lymphopoietin (TSLP), a cytokine implicated in induction of T helper 2 (Th2)-mediated
allergic inflammation, has recently been shown to stimulate solid tumor growth and metastasis. Conversely,
studying mice with clonal loss of Notch signaling in their skin revealed that high levels of TSLP released by
barrier-defective skin caused a severe inflammation, resulting in gradual elimination of Notch-deficient
epidermal clones and resistance to skin tumorigenesis. We found CD4+ T cells to be both required and suffi-
cient tomediate these effects of TSLP. Importantly, TSLP overexpression in wild-type skin also caused resis-
tance to tumorigenesis, confirming that TSLP functions as a tumor suppressor in the skin.INTRODUCTION
The mammalian skin is a model organ used for decades in
chemical carcinogenesis studies and contributed to the recogni-
tion that carcinogenesis is a stepwise process (Hanahan and
Weinberg, 2000). As in other models of cancer, skin tumors arise
as a consequence of intrinsic changes in the initiated cells that
are amplified through interactions with the tumor microenviron-
ment (Campisi, 2005; Kessenbrock et al., 2010; Sneddon and
Werb, 2007). Although immune cells can suppress tumor growth
in the tumor microenvironment, their carcinogenesis-promoting
role is becoming increasingly appreciated (Coussens and
Werb, 2002; Hanahan and Weinberg, 2000, 2011). Because
skin is the largest barrier organ in the body, it is under tight sur-
veillance by the immune system, and even subtle changes in its
cellular differentiation program can alter the overall susceptibility
to cancer by eliciting apersistent inflammatory response (Quigley
et al., 2009). This is partly due to a direct epidermal contribution
to inflammation via secretion of multiple cytokines, such as inter-
leukin (IL)-1, IL-6, and TGF-b (Morasso and Tomic-Canic, 2005).Significance
We demonstrate unequivocally that TSLP triggers a dominant
environment in the skin. Importantly, the antitumormicroenviro
agonists (e.g., Calcipotriol) can prevent and eliminate skin tu
a skin-specific effect, it is intriguing to postulate that TSLP pla
of solid tumor development. Considering the emergence of T
cancers, this report points to an alternative utility for TSLP as
combat and ultimately prevent solid cancers.
494 Cancer Cell 22, 494–505, October 16, 2012 ª2012 Elsevier Inc.Studies in mice with clonal deletion of Notch pathway com-
ponents uncovered a role for Notch in tumor promotion via
induction of a noncell autonomous feed-forward loop between
the epidermis, dermal fibroblasts, and the immune system
(Demehri et al., 2008, 2009b). Notch is a transmembrane
receptor that mediates short-range communication between
adjacent cells (Kopan and Ilagan, 2009). Upon binding to the
ligand presented by a neighboring cell, Notch undergoes prote-
olysis by g-secretase enzyme to release its intracellular domain.
Subsequently, the Notch intracellular domain translocates into
the nucleus and binds to its DNA-binding partner, RBPj, and
regulates its downstream targets in a context-dependent
manner (Kopan and Ilagan, 2009). Notch signaling plays multiple
roles in skin development (Mascia et al., 2012), but in the context
of carcinogenesis, the most relevant role is in promoting supra-
basal differentiation (Blanpain et al., 2006; Demehri et al.,
2009b; Nguyen et al., 2006; Nicolas et al., 2003; Pan et al.,
2004; Rangarajan et al., 2001). Reduction in Notch signaling
leads to aberrant epidermal differentiation and defective barrier
formation, which creates a chronic wound-like environmentantitumor response in a Th2-polarized inflammatory micro-
nment created by TSLP-inducers like low-calcemic vitamin D
mors in wild-type mice. Although our findings may reflect
ys a common tumor suppressor role during the early stages
SLP as a potential therapeutic target in treatment of solid
an antitumor immune factor that can be utilized to optimally
Figure 1. Mice Lacking RBPj in Portions
of Their Epidermis Are Resistant to Skin
Tumorigenesis
(A) The calico pattern of EYFP expression (green)
induced by Msx2-Cre-mediated gene deletion in
a Msx2-Cretg/+; Rosa (LoxP_Stop_LoxP)-Eyfp
(Msx2-Cre/+; RosaEYFP) newborn is shown.
Image taken under tungsten illumination is shown
in magenta. After birth, mutant clones become
evident due to hair phenotypes.
(B) Reduction in Notch signaling dosage in the
skin correlates with shortening of life span and
time to spontaneous tumor formation. This trend,
however, does not extend to mice lacking Rbpj
(green arrow), which live 100 days yet do not
develop any skin tumors. n > 20 in each group; %
indicates the percentage of mice that developed
skin tumors; **p < 0.01, Student’s t test; error bars
represent ± SD. This figure is modified from
Demehri et al., 2009b.
(C and D) Time-to-tumor onset (C; p < 0.0001, log
rank test) and average tumor number (D) of
RBPjCKO and wild-type littermates treated with
the standard DMBA/TPA protocol from 3 to
18 weeks of age are shown. n = 7 for each group;
* p < 0.05, Student’s t test; error bars represent ±
SEM. Genotypes: Msx2-Cretg/+; Notch1flox/flox
(N1CKO),Msx2-Cretg/+; Notch1flox/flox; Notch2flox/+
(N1N2hCKO), Msx2-Cretg/+; Notch1flox/flox;
Notch2flox/+; Notch3/ (N1N2hN3CKO), Msx2-
Cretg/+; Notch1flox/flox; Notch2flox/flox (N1N2CKO),
Msx2-Cretg/+; Ps1flox/flox; Ps2/ (PSDCKO),Msx2-
Cretg/+; Rbpjflox/flox (RBPjCKO).
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ings, mice and humans lacking components of the g-secretase
complex (Presenilin 1 and 2 [Ps1/2], presenilin enhancer 2
[PEN2], APH1 or Nicastrin) have elevated rates of spontaneous
tumor development (Lapins et al., 2001; Li et al., 2007; Wang
et al., 2010; Xia et al., 2001). Additionally, the g-secretase inhib-
itor Semagacestat (LY450139) led to elevated incidence of
skin cancer among the participants in a phase III clinical trial
(Extance, 2010). Importantly, the latency for spontaneous tumor
formation in the epidermis is determined by the degree of dis-
ruption in its differentiation program caused by Notch signaling
loss (Demehri et al., 2009b).
An epidermal-derived cytokine whose level rises as more
Notch signaling is lost in the skin is Thymic Stromal Lymphopoie-
tin (TSLP), which could contribute to the susceptibility of Notch-
deficient skin to tumorigenesis (De Monte et al., 2011; Demehri
et al., 2008, 2009b; Olkhanud et al., 2011; Pedroza-Gonzalez
et al., 2011). TSLP is an IL-7-like cytokine studied mainly in the
context of T helper 2 (Th2)-mediated allergic inflammation in
the skin and lung (Leonard, 2002; Rochman et al., 2009; Ziegler,
2010); overexpression of TSLP is sufficient to promote the devel-
opment of atopic dermatitis and asthma, respectively (Ziegler,
2010). Importantly, transient exposure to an allergen in the pres-
ence of TSLP is sufficient to prime the skin and lung immune
cells, creating long-lasting T cells that can trigger allergic inflam-
mation later (Han et al., 2012; Zhang et al., 2009; Demehri et al.,
2009a). Although TSLP is not expressed in the skin under phys-
iological conditions, keratinocytes are powerful secretors of
TSLP in both humans (Lee et al., 2010) and mice; chronic andCsevere barrier disruption can result in TSLP release into the
serum up to 5,000-fold over its baseline levels (Demehri et al.,
2008; Dumortier et al., 2010; Zhang et al., 2009). Interestingly,
systemic TSLP drives a leukemia-like B cell lymphoproliferative
disease in newbornmice (Demehri et al., 2008), and constitutively
active TSLPR causes acute B-lymphoblastic leukemia in children
(Cario et al., 2010; Hertzberg et al., 2010; Shochat et al., 2011).
TSLP has also emerged recently as a progrowth cytokine in
breast and pancreatic cancers (De Monte et al., 2011; Olkhanud
et al., 2011; Pedroza-Gonzalez et al., 2011). These findings sug-
gest a therapeutic opportunity for TSLP-blocking agents that are
in development for the treatment of allergic diseases (Schmitt,
2011) as cancer immunotherapeutic agents.
Considering the emerging role of TSLP as a potential thera-
peutic target in cancer therapy, we set out to investigate the
role of epidermal-derived TSLP in skin carcinogenesis.
RESULTS
Mice Lacking All Canonical Notch Signaling in the
Epidermis Are Resistant to Skin Carcinogenesis
The Msx2-Cretg/+ line expresses Cre recombinase early, tran-
siently, and only in the dorsal and ventral midline regions of the
skin, generating a calico pattern of gene deletion (Figure 1A).
Stepwise removal of Notch alleles in epidermal keratinocytes
by Msx2-Cretg/+ is associated with a corresponding decline
in differentiation, creation of a wound-like environment and
increased susceptibility to carcinogenesis (Demehri et al.,
2009b; Figures 1A and 1B). Animals lacking all Notch signalingancer Cell 22, 494–505, October 16, 2012 ª2012 Elsevier Inc. 495
Figure 2. Notch Signaling-Deficient Epidermal Clones Regress
with Age
(A) The red dotted line and arrowheads delineate the boundaries of the RBPj-
deficient dorsal epidermis, as determined by hair/epidermal phenotype.
Bottom panel shows a-RBPj antibody staining of RBPj-depleted midline skin
(left) and wild-type skin in the periphery (right) of an 18-week-old RBPjCKO
animal.
(B) The red dotted line and arrowheads delineate the boundaries of the mutant
dorsal epidermis in N1N2CKO and PSDCKO animals. Asterisk marks the
recipients of a sublethal dose of irradiation in the second week of life; repre-
sentative pictures are shown in all panels; scale bars: 1 cm (mice pictures);
50 mm (histology).
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loss of g-secretase enzyme function]) die shortly after birth, not
allowing enough time for spontaneous tumor development
(Figure 1B). RBPj-deficient animals (Msx2-Cretg/+; Rbpjflox/flox;
or RBPjCKO), however, live for 100 days on average, which
is comparable to animals lacking all but one Notch2 allele in
their skin (Msx2-Cretg/+; Notch1flox/flox; Notch2flox/+; Notch3/;
or N1N2hN3CKO). Surprisingly, while 20% of N1N2hN3CKO
mice developed spontaneous skin tumors, none (0/40) of the
RBPjCKO mice that have been examined developed sponta-
neous tumors (Figure 1B).
To further rule out the possibility that the short life span
of RBPjCKO mice masked incipient tumors, we subjected
RBPjCKO mice, maintained through >6 generations of inter-
crossing in a mixed genetic background (C57BL/6 with FVB,
CD1 contribution), to a multistage chemical skin carcinogenesis
model (Yuspa et al., 1994). Three-week-old RBPjCKO and
their wild-type littermates (defined as all mice not inheriting the
Cre transgene) were treated with 25 mg 7,12-dimethylbenz[a]
anthracene (DMBA), followed by a twice-weekly dose of 12-O-
tetradecanoylphorbol-13-acetate (TPA) for 14 weeks. Surpris-
ingly, no tumors were detected in the DMBA/TPA-treated
RBPjCKO animals after 15 weeks of follow-up, whereas the
majority of wild-type littermates developed more than 20 papil-
lomas/mouse (n = 7 in each group, p < 0.0001; Figures 1C and
1D). These results contrast starkly to the enhanced tumor
susceptibility seen in other Notch-deficient animals (Figure 1B;496 Cancer Cell 22, 494–505, October 16, 2012 ª2012 Elsevier Inc.Demehri et al., 2009b). Resistance to DMBA/TPA might reflect
a reduced growth potential of RBPj-deficient keratinocytes
(Blanpain et al., 2006). However, even if this were the case, we
would expect initiated wild-type cells in this environment to
form tumors (Demehri et al., 2009b). Alternatively, resistance to
tumorigenesis in RBPjCKO skin may be due to a switch from
a tumor-promoting environment in N1CKO (Demehri et al.,
2009b) to a tumor-suppressing environment in RBPjCKO skin.
Wild-type Keratinocytes Replace Their Notch
Signaling-Deficient Neighbors over Time
The calico pattern of gene deletion in RBPjCKO animals allowed
us to notice a second, potentially related phenotype. As these
mice aged, the mutant epidermal clones on their dorsal and
ventral surfaces shrank, and RBPj-deficient epidermis eventually
disappeared in the oldest individuals (Figure 2A and data not
shown). Although Msx2-Cretg/+; Notch1flox/flox; Notch2flox/flox
(N1N2CKO); and PSDCKOmice die post weaning due to a lethal
B-lymphoproliferative disorder (Demehri et al., 2008), they did
survive longer if we controlled their B-LPD with a sublethal
dose of irradiation (Demehri et al., 2008). When lethality was
rescued in this manner, we observed a similar regression
of Notch1/2- or Ps1/2-deleted epidermis as N1N2CKO and
PSDCKO animals aged (Figure 2B). This too could reflect a
proliferative disadvantage of Notch signaling-deficient keratino-
cytes or the active process of rejection.
H-Ras-Infected Notch-Deficient Keratinocytes Are
Highly Tumorigenic in Immune-Compromised Mice
To ask if the resistance of RBPjCKO mice to carcinogenesis and
the loss of mutant keratinocytes are due to a low proliferative
capacity, we evaluated their tumor-forming potential in response
to the activated H-Ras oncogene in the nude mouse environ-
ment (Nicolas et al., 2003). First, we isolated keratinocytes
from newborn Rbpjflox/flox and Rbpj+/flox littermates. Cells were
then infected with activated H-Ras-expressing retrovirus, al-
lowed to recover for 24 hr and then infected with Cre-expressing
adenovirus. H-Ras-infected, Cre expressing, Rbpj/ (RBPjKO)
or Rbpj+/ (wild-type) cells (1.5 3 106) were injected subcutane-
ously into nude mice and tumor development was monitored
over time. Importantly, RBPjKO keratinocytes formed large
tumors with histological features of moderately differentiated
squamous cell carcinomas in 30 days, while wild-type keratino-
cytes did not form a significant tumor mass (Figure 3). Similar
results were obtained using g-secretase-deficient (PSDKO)
keratinocytes (Figure 3). These results demonstrate that Notch
signaling-deficient cells are highly proliferative and competent
to form tumors in a T cell-deficient environment. Therefore, we
hypothesized that the apparent resistance of Notch signaling-
deficient animals to skin tumorigenesis is most likely due to the
activation of a tumor-suppressing environment in their skin.
Notch-Deficient Animals Develop Severe Allergic
Skin Inflammation Caused Specifically
by Epidermal TSLP Overexpression
Inflammation can either promote or suppress tumorigenesis
depending on its magnitude and the immune cells involved
(Coussens and Werb, 2002; Schreiber et al., 2011). In sharp
contrast to the mild inflammation, dermal fibroplasia and
Figure 3. H-Ras-Infected RBPjKO or PSDKO Keratinocytes Are
Highly Tumorigenic in Nude Mice
(A) Schema showing the experimental procedure. Cells are infected with
retrovirus containing oncogenic H-Ras and then with Adeno-Cre to delete the
floxed alleles. H-Ras-infected RBPjKO or PSDKO and wild-type cells injected
subcutaneously into the right and left flanks of the nude mice, respectively.
(B) Nude mice with palpable tumors (red circles) are harvested 30 days after
the injection. Hematoxylin and eosin (H&E) and a-RBPj antibody stainings on
a tumor formed by RBPjKO keratinocytes are shown. Representative pictures
are shown; scale bars: 1 cm (mice pictures), 50 mm (histology).
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in N1CKO skin (Demehri et al., 2009b), RBPjCKO skin exhibited
a significant accumulation of leukocytes (CD45+ cells) beneath
the RBPj-deficient epidermal clones (Figure 4A). To test if this
high level of dermal inflammation could have a suppressing
effect on tumor growth (Coussens and Werb, 2002), we first
examined the effect of immunosuppressant drugs on DMBA-
treated RBPjCKO mice. Treatment with the maximum tolerable
doses of Dexamethasone or Methotrexate did not significantly
reduce inflammation in RBPjCKO mice, nor did it affect the
rejection of mutant skin cells or allow tumor formation (Figures
S1A and S1B available online). Next, we examined if TNFa,
a prominent proinflammatory cytokine also overexpressed in
Notch signaling-deficient skin (Dumortier et al., 2010), contrib-
utes to skin inflammation in RBPjCKO animals. The levels of
skin inflammation, tumor resistance, and mutant skin patch
rejection in Msx2-Cretg/+; Rbpjflox/flox; TnfrI/; TnfrII/ miceCwere indistinguishable from RBPjCKO littermates (Figure S1C),
indicating that TNFa was not necessary for theses phenotypes.
RBPjCKO keratinocytes produced significantly higher levels
of TSLP than those seen in the tumor-prone N1CKO and
N1N2hN3CKO animals (Figure 4B), driving the severe Th2
inflammation seen in RBPjCKO skin (Demehri et al., 2009a;
Dumortier et al., 2010; He et al., 2008). Therefore, we next exam-
ined the effect of loss of TSLP signaling on inflammation by
generating RBPjCKO mice that lack the TSLP receptor by
deleting genes encoding its subunits (Il7ra or Crlf2 [Tslpr]).
Il7ra/ (IL7raKO) mice were used in place of Tslpr/
(TSLPRKO) mice because Rbpj and Tslpr are linked on the
same arm of chromosome 5, and thus we were unable to gen-
erate RBPjCKO;TSLPRKO animals. Deleting Il7ra in RBPjCKO
or N1N2CKO (Msx2-Cretg/+; Rbpjflox/flox; Il7ra/ or RBPjCKO;
IL7raKO, Msx2-Cretg/+; Notch1flox/flox; Notch2flox/flox; Il7ra/ or
N1N2CKO; IL7raKO) mice led to a marked reduction in skin
inflammation (Figure 4C; Figure S1D). To confirm that this effect
was specific to TSLP and not an indirect consequence of
reduced lymphocyte numbers in IL7raKO mice (Peschon et al.,
1994), we deleted Tslpr in PSDCKO animals (Msx2-Cretg/+;
Ps1flox/flox; Ps2/; Tslpr/ or PSDCKO; TSLPRKO), which
significantly prolonged their lifespan (Dumortier et al., 2010).
As with N1N2CKO; IL7raKO and RBPjCKO; IL7raKO, inflam-
mation was greatly reduced in PSDCKO;TSLPRKO animals
(Figure S1D). Taken together, these results demonstrate a
central role for TSLP in regulating the level of inflammation in
Notch-deficient skin.
Blocking TSLP Signaling in Notch-Deficient
Animals Results in the Expansion of the Mutant
Skin and Tumorigenesis
RBPjCKO;IL7raKO animals showed a clear reversal of the two
phenotypes unique to RBPjCKO mice. First, RBPj-deficient
epidermal clones expanded dramatically in RBPjCKO;IL7raKO
mice, forming numerous hypertrophic cysts (Figure 4D).
Together with the data in Figure 3, this result excludes a prolifer-
ative defect in RBPj-deficient keratinocytes. Second, RBPjCKO;
IL7raKO mice developed spontaneous, invasive dermal and
exophytic tumors over time (Figures 4D and S1E). N1N2CKO;
IL7raKO and PSDCKO;TSLPRKO animals also showed ex-
pansion of their mutant skin territories (Figure 4D; Dumortier
et al., 2010 and the accompanying paper by Di Piazza et al.).
All RBPjCKO;IL7raKO and PSDCKO;TSLPRKO animals eventu-
ally developed cancerous lesions that invaded through the
subcutaneous muscle layer at 10 to 15 weeks of age (Figures
4D and S1E). Treating the skin of these animals with a single
dose of DMBA further revealed their susceptibility to tumorigen-
esis (Figure S1E). Therefore, eliminating TSLP reception reduced
inflammation, restored a tumor-promoting environment remi-
niscent of the N1CKO mice, and uncovered the underlying
cancer-prone phenotype in mice lacking canonical Notch
signaling in their skin. Whether viruses contributed to tumor
formation in these animals remains to be determined.
The Adaptive Immune System Mediates the Effects
of TSLP on Skin Rejection and Tumor Resistance
In order to determine if bone marrow (BM)-derived immune cells
mediated the effects of TSLP on skin rejection and resistanceancer Cell 22, 494–505, October 16, 2012 ª2012 Elsevier Inc. 497
Figure 4. Blunting the Skin Inflammation
by Blocking TSLP Signaling in Notch
Signaling-Deficient Animals Results in
Mutant Skin Expansion and Tumorigenesis
(A) H&E and CD45 antibody stainings show the
level of skin inflammation in RBPjCKO animals
compared to the tumor-prone N1CKO and
N1N2hN3CKO mice. Scale bars: 50 mm.
(B) The circulating TSLP levels during the second
week of life are compared among the allelic series
of Notch-deficient animals. *p < 0.05, Student’s
t test; error bars represent ± SD. This figure is
modified from Demehri et al., 2008.
(C) H&E and CD45 antibody stainings highlight
the level of dermal inflammation in RBPjCKO;
IL7raKO animals that lack TSLP signaling. Scale
bars: 50 mm.
(D) Gross and microscopic features of RBPjCKO;
IL7raKO, N1N2CKO;IL7raKO and PSDCKO;
TSLPRKO skin are compared to those of
RBPjCKO, N1N2CKO, and PSDCKO littermates,
respectively. Asterisks mark the recipients of
a sublethal dose of irradiation in the second week
of life; insets: tumors penetrating the muscle
layer; scale bars: 1 cm (mice pictures), 200 mm
(histology); representative pictures are shown in
all panels.
See also Figure S1.
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class I haplotypes (Figures S2A–S2C) and reconstituted the
immune system of lethally irradiated RBPjCKO;IL7raKO and
PSDCKO;TSLPRKO mice with BM from their wild-type litter-
mates. We monitored their response to DMBA treatment
following BM transplantation (BMT). Interestingly, wild-type BM
restored resistance to DMBA-induced tumors in RBPjCKO;
IL7raKO and PSDCKO;TSLPRKO mice; concomitantly, the
mice gained the ability to eliminate their mutant skin cells
(Figures 5A, 5B, and S2D). In a complementary set of experi-
ments, we reconstituted the immune system of lethally irradiated
RBPjCKO and PSDCKO mice with BM from their IL7raKO and
TSLPRKO littermates, respectively, to determine if a protumor
environment would be re-established. This immune reconstitu-
tion, however, failed to establish tolerance, and no DMBA-
induced tumors formed (Figure S2E). This could be explained
by the persistence of irradiation-resistant activated and memory
T cells in the mutant animals at the time of transplantation
(Figure S2F). Together, these findings demonstrate that BM-
derived immune cells act downstream of TSLP, and suggest
that the effector cell type(s) formed in RBPjCKO and PSDCKO
are resistant to lethal doses of irradiation.
Based on the findings above, we focused on the immune cell
repertoire in RBPjCKO (Figure S2G; Demehri et al., 2009b) and
targeted cell types that are known to be resistant to irradiation498 Cancer Cell 22, 494–505, October 16, 2012 ª2012 Elsevier Inc.(Murphy et al., 1987), express TSLP
receptors, and mediate tumor resistance
and skin rejection (Vesely et al., 2011).
Based on these criteria, we chose to
delete CD8+ cytotoxic T lymphocytes
(CTLs) and mast cells in RBPjCKOanimals. Genetic depletion of these cells in RBPjCKO;CD8a/
and RBPjCKO;Kitwsh/wsh did not cause any alteration in the
RBPjCKO skin phenotypes, suggesting that neither cell type is
necessary to mediates the effects of TSLP (Figure S2H). In
a separate set of experiments, we used previously described
depleting antibodies (Rogers and Unanue, 1993; Shankaran
et al., 2001) to deplete CD4+ T cells, CD8+ T cells, natural killer
(NK) cells, or granulocytes in RBPjCKO animals. Although we
achieved the complete depletion of these cell types in the blood,
we failed to alter rejection or tumor resistance phenotypes in
RBPjCKO mice (Figure S2I), most likely due to the resistance
of activated T cells to depletion (Figure S2J). From these sets
of experiments, we concluded either that (1) the cell type(s)
mediating the effects of TSLP were resistant to antibody deple-
tion and irradiation, such as activated/memory T cells (Jamali
et al., 1992; Murphy et al., 1987), or (2) not present among the
cell types depleted with the antibodies we used.
To distinguish these possibilities systematically, we focused
on RBPjCKO;IL7raKO and PSDCKO;TSLPRKO mice, which
never establish TSLP-dependent tumor resistance and thus
lack activated effector cells. Having established that wild-type
BM can reconstitute the skin rejection and tumor resistance in
RBPjCKO;IL7raKO and PSDCKO;TSLPRKO animals (Figures
5A and 5B), we reconstituted the immune cells of lethally
irradiated RBPjCKO;IL7raKO and PSDCKO;TSLPRKO mice
Figure 5. CD4+ T Cells Mediate the Effects of TSLP on Notch-Deficient Skin Rejection and Tumor Resistance
(A and B) The skin phenotypes of RBPjCKO;IL7raKO (A) and PSDCKO;TSLPRKO (B) animals are analyzed 8 weeks after BMT from wild-type littermates,
Rag2/,gc/ (Rag2gcKO) or Rag2/ (Rag2KO) animals. Note that Rag2gcKO and Rag2KO donors lack T and B cells. The level of dermal inflammation, the
rejection of the mutant keratinocytes, the formation of hypertrophic cysts and the development of DMBA-dependent exophytic tumors are scored in the recipient
animals at 10 weeks of age. BMT from TSLP receptor-deficient littermates are used as controls. *p < 0.05 compared to wild-type BM donor group.
(C and D) Two-week-old RBPjCKO;IL7raKO (C) and PSDCKO;TSLPRKO (D) pupswere irradiated with 450-cGy and underwent adoptive T cell transfer using wild-
type CD4+, wild-type CD8+ or TSLPR-deficient CD4+ T cells isolated from the spleens of their littermates as shown in the schematic diagrams. The level of dermal
inflammation, the rejection of the mutant keratinocytes, the formation of hypertrophic cysts, and the development of DMBA-dependent exophytic tumors are
documented in the recipient animals at 10 weeks of age. *p < 0.05 compared to wild-type CD4+ T cell donor group.
(E) Two-week-old RBPjCKO;IL7raKO mice were treated with depleting antibodies (anti-CD4 or anti-CD8a; black arrows), lethally irradiated 2 days later and
transplanted with T cell-depleted c-Kit+ BM progenitor cells from their wild-type littermates as shown in the schematic diagram. Two days later, the animals were
treatedwith one doseDMBAwhile continuing to receive aweekly intraperitoneal injection of the indicated depleting antibody for 10weeks. Flow cytometry shows
the status of CD4+ and CD8+ T cells in the peripheral blood of RBPjCKO;IL7raKO mice transplanted with c-Kit+ wild-type BM and treated with anti-CD4 or anti-
CD8a antibody oneweek after the last antibody injection. Blood CD45+ leukocytes are traced in the figure. Note that PE-conjugated anti-CD8b antibody is used to
detect CD8+ cells.
(F) RBPjCKO;IL7raKOmice transplanted with c-Kit+ BMcells and treated with anti-CD4, anti-CD8a, or IgG control antibodies are compared. Bar graphs show the
average number of DMBA-dependent exophytic tumors in each treatment group. *p < 0.05 compared to IgG control-treated group. For all experiments, mice
were followed up to 90 days of age for exophytic tumor count; at least five mice were analyzed in each group; error bars on all bar graphs represent ± SD;
representative pictures are shown; scale bars: 1 cm.
See also Figure S2.
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DMBA-treated RBPjCKO;IL7raKO and PSDCKO;TSLPRKO
animals transplanted with Rag2/ BM failed to reject mutant
skin, which formed hypertrophic cysts and developed tumorsC(Figures 5A, 5B, and S2K). This clearly demonstrates that adap-
tive immune cells responding to TSLP are required for the tumor
resistance and mutant skin rejection in Notch signaling-deficient
animals.ancer Cell 22, 494–505, October 16, 2012 ª2012 Elsevier Inc. 499
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to Mediate the Effects of TSLP on Skin Rejection
and Tumor Resistance
Among adaptive immune cell types, activated T cells are known
to be resistant to irradiation and persist after antibody depletion
(Jamali et al., 1992; Murphy et al., 1987). Considering that mice
lacking CD8+ CTLs retained their tumor resistance and skin
rejection phenotypes (RBPjCKO;CD8a/; Figure S2H), CD4+
T cells emerged as the prime candidate mediating the effects
of TSLP in our model of Notch signaling-deficient skin. To test
this hypothesis, 2 3 106 CD4+ or CD8+ T cells from wild-type
littermates were transferred to sublethally irradiated RBPjCKO;
IL7raKO and PSDCKO;TSLPRKO newborns. Adoptive transfer
of wild-type CD4+ T cells to RBPjCKO;IL7raKO and PSDCKO;
TSLPRKO mice re-established the tumor resistance and mutant
skin rejection phenotypes in these animals, but adoptive transfer
of wild-type CD8+ CTLs did not (Figures 5C, 5D, and S2L). As
expected, wild-type CD4+ T cells transferred into RBPjCKO;
IL7raKO animals underwent Th2 differentiation (Figure S2M).
This finding demonstrates that CD4+ Th2 cells competent to
receive the TSLP signal are sufficient to reconstitute the protec-
tive effects of TSLP in TSLPR and Notch signaling-deficient skin.
To ask if CD4+ T cells were required to initiate the effects of
TSLP, lethally irradiated RBPjCKO;IL7raKO mice were trans-
planted with c-Kit+ BM cells from their wild-type littermates
and treated continually with anti-CD4, anti-CD8, or IgG control
antibodies (Figure 5E). Injecting the RBPjCKO;IL7raKO animals
with depleting antibodies weekly resulted in effective and sus-
tained depletion of targeted cell types (Figure 5E). Importantly,
only the RBPjCKO;IL7raKO mice that received wild-type BM
progenitors plus anti-CD4 antibody retained their mutant
cells, formed hypertrophic cysts, and developed skin tumors in
response to DMBA (Figure 5F), despite the possible presence
of a few mature CD4+ cells, which differentiated in the donor
environment. In all BMT and adoptive T cell transfer experiments,
the presence of donor-derived hematopoietic cells was
confirmed at the conclusion of the study (Figure S2N). Together,
these data demonstrate that naive CD4+ T cells constitute the
cell type receiving the TSLP signal and coordinating the immune
response necessary to reject Notch signaling-deficient skin and
prevent tumorigenesis in this context.
Epidermal TSLP Overexpression in Wild-type Skin
Prevents Skin Tumorigenesis
To test if TSLP overexpression can mobilize the antitumor
immune response in a background free of Notch mutations, we
used chemical and genetic approaches to upregulate epidermal
TSLP expression in wild-type animals subjected to the multi-
stage chemical skin carcinogenesis model. First, we used the
topical application a low-calcemic Vitamin D3 analog (calcipo-
triol; known also as MC903 or Dovonex) to induce epidermal
TSLP expression in CD1 female mice (Li et al., 2006). CD1
genetic background was chosen for these studies because the
skin inflammation caused by TSLP overexpression downstream
of calcipotriol treatment did not result in a full-blown AD-like
disease (Demehri et al., 2009a). Mice were treated with a single
initiating dose of DMBA (125 mg), followed by a twice-weekly
dose of TPA (4 mg) for 14 weeks. The test group was also treated
with topical calcipotriol (32 nmol) and controls with carrier only500 Cancer Cell 22, 494–505, October 16, 2012 ª2012 Elsevier Inc.(EtOH) five times a week during the 14 weeks of TPA application.
Strikingly, the majority of carrier-only treated animals developed
papillomas, whereas only two of the calcipotriol-treated animals
transiently developed papillomas during 15 weeks of follow-up
(n = 10 for each group, p < 0.0001; Figures 6A and 6B).
To investigate if calcipotriol application can affect existing skin
tumors, we randomly divided the tumor-bearing CD1 animals
from the carrier-only treatment group (Figures 6A and 6B)
into two groups at the end of the TPA treatment period. One
subgroup received calcipotriol five times weekly, whereas the
other received carrier only. Bothweremonitored for an additional
7 weeks. While tumors on the carrier-treated animals continued
to grow in size, tumors on the calcipotriol-treated animals shrank
over time (p < 0.05 at weeks 6 and 7, Figures 6C and 6D).
It is possible that the effects observed above were related
to vitamin D signaling, independent of TSLP expression in the
skin. To confirm that the antitumor effects are mediated through
TSLP, we examined the tumor susceptibility of transgenic
animals that overexpress TSLP in basal keratinocytes. Consis-
tent with the proposed role for TSLP, K14-Tslptg/+ (K14-TSLPtg)
female animals treated once with 100 mg DMBA followed by
4 mg TPA twice weekly for 14 weeks showed significant resis-
tance to tumorigenesis compared to their wild-type littermates
(n = 22 for K14-TSLPtg group and 21 for wild-type group, p <
0.0001 log rank test, Figures 6E and 6F). The serum TSLP
measurements confirmed the overexpression of TSLP in calci-
potriol-treated wild-type and K14-TSLPtg animals (Figure 6G).
These results clearly demonstrate that the tumor-suppressor
effect of TSLP in the skin can be extended to wild-type animals
and that TSLP can prevent tumorigenesis as well as inhibit
growth of existing tumors.
DISCUSSION
The main finding of this report is that upregulation of epidermal
TSLP can generate a dominant and lasting antitumor CD4+
T cell response in a Th2 inflammatory microenvironment
(Demehri et al., 2009a), protecting animals from spontaneous
and chemically-induced skin tumors. These cells orchestrate
the recognition and elimination of proliferating precancerous
cells. This is in stark contrast to the previously described protu-
mor function of Th2-polarized inflammation (Johansson et al.,
2008) and of TSLP (De Monte et al., 2011; Olkhanud et al.,
2011; Pedroza-Gonzalez et al., 2011). Importantly, we show
that chemical induction of TSLP expression in wild-type animals
with DMBA-induced papillomas results in tumor regression. This
latter finding suggests that TSLP upregulation may provide
therapeutic benefits in treating skin tumors and perhaps for
other solid tumors.
TSLP is a pleiotropic cytokine involved in several immune
processes (Ziegler and Artis, 2010). In the skin and the lung,
TSLP is expressed in response to barrier disruption (Demehri
et al., 2008), where it can skew CD4+ T cell differentiation toward
a Th2 subtype and mediate allergic inflammation (Al-Shami
et al., 2004; Tanaka et al., 2009; Ziegler and Artis, 2010; Leo-
nard, 2002). TSLP serum levels can be a sensitive readout for
the degree of disruption in epidermal differentiation/barrier
integrity (Demehri et al., 2008). Epidermal Notch1 deletion
results in mild disruption in epidermal differentiation, which
Figure 6. TSLP Creates a Tumor-Suppressing Environment in the Wild-type Skin
(A and B) DMBA/TPA treated CD1wild-type animals were topically treated with calcipotriol or carrier (EtOH), (A) time to tumor onset (p < 0.0001, log rank test) and
(B) average number of tumors among tumor-bearing animals are shown. n = 10 for each group; error bars represent ± SEM; *p < 0.01, Student’s t test.
(C and D) The eight tumor-bearing carrier-treatedmice shown in (A and B) were randomly divided into two groups at the end of the 15-week DMBA/TPA treatment
course. The ‘‘test’’ groupwas treatedwith 32 nmol calcipotriol while the ‘‘control’’ group continued to receive carrier alone 5 times per week. (C) After an additional
7-week treatment period, the tumor burdens of the calcipotriol-treated and carrier-treated mice were compared. n = 4 in each group; *p < 0.05, Student’s t test;
error bars represent ± SD. (D) The representative images show the size of the remaining tumors in calcipotriol-treated versus carrier-treated mice at the end of
the 7-week follow-up period. Tumors are highlighted with circles; scale bars: 1 cm.
(E and F) K14-TSLPtg female mice and their wild-type female littermates treated with DMBA/TPA are compared for (E) time to tumor onset (p < 0.0001, log rank
test) and (F) average tumor number among tumor-bearing animals. n = 22 for K14-TSLPtg group and n = 21 for wild-type group; error bars represent ± SEM; *p <
0.01, Student’s t test.
(G) Circulating TSLP levels in calcipotriol-treated and K14-TSLPtg animals were compared to their controls. Error bars represent ± SD; *p < 0.0001 compared to
wild-type group, Student’s t test.
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TSLP Overexpression Protects from Skin Cancerforms a tumor-promoting environment dominated by Gr-1+
CD11b+ myeloid suppressor cells and soluble factors (Demehri
et al., 2009b). The contribution of TSLP to this tumor-promoting
skin environment remains to be determined. Others have shown
that TSLP is responsible for promoting tumor growth and
metastasis in pancreatic and breast cancer (De Monte et al.,
2011; Olkhanud et al., 2011; Pedroza-Gonzalez et al., 2011).
However, once all Notch-signaling is inactivated, high TSLP
levels help establish a potent tumor-suppressing response.
The observation that calcipotriol treatment is capable of
shrinking pre-existing tumors argues against a model in which
TSLP may have a protective effect on the early stages of
tumorigenesis but a promoting effect on later stages of tumor
growth and metastasis, but this is still feasible. There are other
possible explanations for these conflicting findings: TSLP
tumor-suppressor effect may be skin-specific; alternatively,
based on observations in an allelic series of Notch-deficient
mice, TSLP levels may determine whether it promotes or inhibits
tumor development and growth. The tipping point may vary
according to the strength of the protumor environment in
a specific context. Support for the latter comes from the obser-
vations that higher TSLP levels are needed to establish a tumor-
resistant phenotype in the tumor-prone Notch mutant animals
than in the otherwise wild-type K14-TSLPtg animals. Below
this hypothetical threshold, TSLP will have a neutral or tumor-Cpromoting effect; above it, TSLP acts as a potent tumor-
suppressor. These concepts need to be formally tested in future
studies. Nonetheless, here we report that, in both a neutral and
a protumor microenvironment, TSLP concentrations capable of
creating a CD4+ T cell-mediated antitumor response can be
reached. Once achieved, activated CD4+ T cells not only identify
and prevent growth of transformed cells but also mediate the
rejection of Notch signaling-deficient cells.
In the Msx2-Cre animals, large territories of mutant tissue are
embedded in wild-type skin. Therefore, the global resistance of
calico RBPjCKO skin to chemical carcinogens suggests that
the wild-type keratinocytes harboring an activated H-Ras
allele are being suppressed alongside mutant cells with three
different Notch-deficient genotypes (i.e., RBPjCKO, N1N2CKO
or PSDCKO). Importantly, TSLP-activated CD4+ T cells do not
target the normal skin cells in the same animal as they proliferate
to replace the rejected mutant ones. Based on these observa-
tions, we conclude that CD4+ T cells conditioned by high local
TSLP concentrations must recognize immunogenic epitope(s)
arising independent of Notch signaling in cells with abnormal
differentiation. This protective activity does not arise in animals
that have CD4+ T cells that lack the TSLP receptor, that have
low local TSLP concentrations, or that do not have CD4+
T cells. It is important to note that CD4+ T cell activation by
TSLP can occur even if all other tissues and hematopoieticancer Cell 22, 494–505, October 16, 2012 ª2012 Elsevier Inc. 501
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blind to TSLP by germline deletion of either TSLP receptor arms
(Il7ra or Crlf2/Tslpr), as shown in the context of allergic disease
where TSLP acts directly on CD4+ T cells (Al-Shami et al., 2005;
Rochman et al., 2007; Rochman and Leonard, 2008). These
data establish that TSLP-responsive CD4+ T cells are both
sufficient and required to create the tumor suppressingmicroen-
vironment, likely by recruiting several cytotoxic immune effector
cells, including CTLs, NK cells, and macrophages to the skin.
Considering that TSLP promotes Th2 differentiation in Notch
signaling-deficient mice (data not shown; Al-Shami et al., 2004;
Demehri et al., 2009a; Tanaka et al., 2009; Ziegler and Artis,
2010), we propose that the CD4+ Th2 cells are initiating the
effects of TSLP. The exact nature of the antigens they are
reacting to, and whether they are keratinocyte-specific, remain
to be addressed in future studies. Once activated, the CD4+
Th2 cells home to the skin and form a lasting pool of ‘‘memory’’
cells that could not be eradicated with anti-CD4 antibody or
irradiation (Figure 4D). This observation is very exciting because
it demonstrates that TSLP induces a lasting antitumor immunity
that is achieved by targeting antigens specific to at least some
tumor cells. This protection can be achieved by application of
a TSLP-inducer (calcipotriol) to fully developed skin tumors in
wild-type animals. It remains to be determined if TSLP can
also stimulate the regression of other solid tumors besides the
ones formed in the skin.
In an accompanying paper, a similar set of observations is
reported. Both studies report an antitumor function for TSLP
in Notch-deficient skin, both demonstrate that this function of
TSLP can also be elicited in animals with intact Notch signaling,
and both find an important role for CD4+ T cells. However,
whereas our colleagues report that CD8+ CTLs mediate the
tumor resistance phenotype, we do not find CD8+ T cells to be
necessary in our model. In their study, Notch alleles are deleted
globally in the skin after birth using an inducible basal keratino-
cyte Cre. Consequently, deletion occurs during the hair follicle
growth phase, the hair follicle bulge remains intact and the
immune system matures in the absence of TSLP or tumor anti-
gens. This deletion paradigm precludes monitoring the rejection
of mutant skin clones. In our mice, the immune system matures
in the presence of TSLP, which begins to accumulate in utero at
E16.5 (Demehri et al., 2008), and in the presence of the antigens
presented by mutant cells and by tumor cells later on. Moreover,
in our mice, the hair follicle is destroyed by P10 and the bulge
never forms because the outer root sheath of the hair follicles
adopts an epidermal fate right after birth (Demehri et al., 2008).
It is conceivable that some of the difference between the two
studies reflects methodological differences, but it is hard to
explain why CD8+ CTLs do not contribute to our system, yet
provide the bulk of protection for their Notch-deficient mice.
The explanation may lie in the difference between the tumor cells
of origin, the timing of the Notch signaling deletion, or the
differences in background (ours is mixed, whereas theirs is
pure C57/B6). The differential role of CTLs in these two experi-
mental paradigms needs to be addressed in future studies.
The accompanying study demonstrates that the cystic tumors
arise via a Wnt/b-catenin-dependent mechanism from bulge-
derived hair follicles, whereas our tumors originate from
epidermal cells that did not accumulate nuclear b-catenin prior502 Cancer Cell 22, 494–505, October 16, 2012 ª2012 Elsevier Inc.to tumor formation (Demehri et al., 2009b). Taken together,
however, the differences between the studies support the
conclusion that TSLP can provide immunological protection
against skin cancer and support the speculation that it may do
the same in other types of solid tumors.
In summary, this study and the accompanying paper by Di
Piazza et al. identify a previously unrecognized role for TSLP in
inducing a robust antitumor response in several experimental
paradigms (Notch loss of function, Wnt gain of function [Di
Piazza et al., 2012 in this issue of Cancer Cell] and DMBA-
induced H-Ras dependent tumors). Moreover, these studies
demonstrate that TSLP exerts its antitumor effects through a
CD4+ Th2 inflammatory environment. Our findings may explain
why some individuals who suffer from Th2-dominant allergic
disorders display reduced risk of developing certain types of
cancers, including nonmelanoma skin cancers (Gandini et al.,
2005; Hwang et al., 2012; Prizment et al., 2007; Vajdic et al.,
2009; Wang and Diepgen, 2005). Importantly, therapeutic
exploitation of this mechanism seems within reach given the
efficacy of calcipotriol, a Food and Drug Administration-




The mutant animals (listed in the Supplemental Experimental Procedures
section) were generated according to the methods outlined in our previous
report (Pan et al., 2004). All of the mice were housed in theWashington Univer-
sity animal facility, and all experiments were performed in accordance with
relevant institutional and national guidelines and regulations approved by the
Animal Studies Committee atWashington University. The pedigreed RBPjCKO
cohortwasmaintained inmixedFVB,C57BL/6, andCD1genetic backgrounds,
which were overall more susceptible to DMBA/TPA skin carcinogenesis. All
other animals were kept in mixed C57BL/6 and CD1 genetic backgrounds
and, therefore, were relatively more resistant to chemical skin carcinogens.
In all cancer experiments, age-matched littermates were compared.
Msx2-Cretg/+; Rosa-LSL-Eyfp mouse was imaged at P0 using Leica stereo-
scopic fluorescence microscope with regular light (rendered magenta in Fig-
ure 1A) or enhanced yellow fluorescent protein (EYFP) filter. In studies related
to mutant skin rejection, spontaneous/DMBA-induced tumorigenesis and life
span, mice were photographed with a digital camera weekly and monitored
for onset, number, and size of tumors and any sign of failure to thrive. Moribund
mice were euthanized and skin, tumors, blood, spleen, and lymph nodes were
harvested.
Chemical Skin Carcinogenesis Studies
For RBPjCKO DMBA/TPA experiments, 3-week-old mutant mice and Cre-
negative wild-type littermates were treated with the standard protocol for
skin chemical carcinogenesis model, as previously described (Nicolas et al.,
2003). RBPjCKO mice received one dose of 25 mg DMBA (Sigma, St. Louis)
followed in a week by biweekly treatment with 4 mg TPA (Sigma) for 14 weeks.
In K14-TSLPtg and CD1 carcinogenesis experiments, mice were treated with
125 mg DMBA (CD1, Calcipotriol treatment) or 100 mg DMBA (K14-TSLPtg).
In all of the experiments, adult mice were shaved under anesthesia 2 days prior
to treatment with DMBA to ensure the hair follicles were in the second telogen.
In studies where tumorigenesis was induced with one dose of DMBA, the
mutant animals received a single dose of 125 mg DMBA in 100 ml of acetone
during the second week of life, after the mice were subjected to any other
experimental procedures including irradiation, BMT, or adoptive T cell transfer.
BMT
The recipient mice were lethally irradiated with 950-cGy in the second week of
life and transplanted with unfractionated BM cells from their littermates,
Cancer Cell
TSLP Overexpression Protects from Skin CancerRag2/;gc/ or Rag2/ animals as previously described (Zhang and Ren,
1998). All transplanted animals were maintained on antibiotics containing
water to prevent infection.
Adoptive T Cell Transfer
For T cell isolation, splenocytes were positively selected for CD4 or CD8
surface expression using CD4 or CD8 MicroBeads, respectively, followed
by negative selection to remove any CD11c+ dendritic cells using CD11c Mi-
croBeads (Miltenyi Biotec, Auburn, CA). RBPjCKO;IL7raKO and PSDCKO;
TSLPRKO mice were irradiated with 450-cGy during the second week of life
and injected intravenously with 2 3 106 CD4+ or CD8+ T cells isolated from
the spleen of their littermates.
BMT and Antibody Depletion
RBPjCKO;IL7raKO newborn mice received intraperitoneal injection of 750 mg
anti-CD4 (GK1.5; Bio X Cell, West Lebanon, NH), anti-CD8 (YTS; Bio X Cell), or
IgGControl antibody (Sigma) in the secondweek of life. Forty-eight hours later,
the mutant animals received BMT using c-Kit+ BM progenitors (lacking T cells)
from their wild-type littermates isolated using CD117 MicroBeads and
magnetic columns according to manufacturer’s protocol (Miltenyi Biotec
Inc., Auburn, CA). Each recipient was injected intravenously with 2 3106
c-Kit+ BM cells in 100 ml PBS+2% FBS. The mutant animals were then
treated topically with one dose of DMBA and continued to receive 250 mg of
the depleting antibody weekly. Mice were monitored for skin rejection and
tumor formation weekly and harvested at P90.
Statistical Analysis
Except for calcipotriol studies performed on wild-type CD1 animals, all of the
animals used in this study were kept on mixed genetic backgrounds in a pedi-
greed colony (i.e., all animals are logged into a database). To minimize the
confounding effects of strain or family background on tumor outcomes, we
only compared gender-matched littermates in each cancer study. Using the
power analysis described previously (Demehri et al., 2009b), we determined
the number of animals needed in each chemical skin carcinogenesis study.
As the test of significance between the study groups, we used log rank test
for ‘‘time-to-tumor onset’’ and Student’s t test for tumor counts, serum TSLP
levels, and other quantitative measurements.
SUPPLEMENTAL INFORMATION
Supplemental Information includes two figures and Supplemental Experi-
mental Procedures and can be found with this article online at http://dx.doi.
org/10.1016/j.ccr.2012.08.017.
ACKNOWLEDGMENTS
We would like to thank Drs. Robert Schreiber, Kenneth Murphy, Barry Sleck-
man, Emil Unanue, Wayne Yokoyama, Deepta Bhattacharya, Takeshi Egawa,
Suellen Greco, Omar Jassim, and David Denardo for providing us with many
valuable experimental tools, ideas, and comments on the manuscript, and the
members of the Kopan laboratory for their suggestions during the course of
this study. We wish to thank Dr. Freddy Radtke and his coworkers for sharing
their unpublished results with us during the course of these experiments. We
would like to thank Dr. Gail Martin for providing Msx2-Cretg/+ mice, Dr. Tom
Gridley for Notch2flox/flox mice, Dr. Jie Shen for Ps1flox/flox mice, Dr. Tasuku
Honjo for Rbpjflox/flox mice, Dr. Andrew Farr for the K14-TSLPtg mice, and
Dr. Warren Leonard for Tslpr/ mice. We would like to thank Rheumatic
Disease Core Center’s Speed Congenics Lab at Washington University for
their assistance with genotyping. S.D., M.T., and R.K. are supported by Grant
GM55479-16 from NIH/NIGMS. S.M. and L.J.Y. were supported by funds
from the American Asthma Foundation (Grant 09-0234). A.T. was supported
by funds from NIH 2 U19 AI070489-09. The flow cytometry core is supported
by P30 CA091842.
Received: February 8, 2012
Revised: June 13, 2012
Accepted: August 21, 2012
Published: October 15, 2012CREFERENCES
Al-Shami, A., Spolski, R., Kelly, J., Fry, T., Schwartzberg, P.L., Pandey, A.,
Mackall, C.L., and Leonard, W.J. (2004). A role for thymic stromal lymphopoie-
tin in CD4(+) T cell development. J. Exp. Med. 200, 159–168.
Al-Shami, A., Spolski, R., Kelly, J., Keane-Myers, A., and Leonard, W.J. (2005).
A role for TSLP in the development of inflammation in an asthmamodel. J. Exp.
Med. 202, 829–839.
Blanpain, C., Lowry, W.E., Pasolli, H.A., and Fuchs, E. (2006). Canonical notch
signaling functions as a commitment switch in the epidermal lineage. Genes
Dev. 20, 3022–3035.
Campisi, J. (2005). Senescent cells, tumor suppression, and organismal aging:
good citizens, bad neighbors. Cell 120, 513–522.
Cario, G., Zimmermann, M., Romey, R., Gesk, S., Vater, I., Harbott, J.,
Schrauder, A., Moericke, A., Izraeli, S., Akasaka, T., et al. (2010). Presence
of the P2RY8-CRLF2 rearrangement is associated with a poor prognosis in
non-high-risk precursor B-cell acute lymphoblastic leukemia in children
treated according to the ALL-BFM 2000 protocol. Blood 115, 5393–5397.
Coussens, L.M., and Werb, Z. (2002). Inflammation and cancer. Nature 420,
860–867.
De Monte, L., Reni, M., Tassi, E., Clavenna, D., Papa, I., Recalde, H., Braga,
M., Di Carlo, V., Doglioni, C., and Protti, M.P. (2011). Intratumor T helper
type 2 cell infiltrate correlates with cancer-associated fibroblast thymic
stromal lymphopoietin production and reduced survival in pancreatic cancer.
J. Exp. Med. 208, 469–478.
Demehri, S., Liu, Z., Lee, J., Lin, M.H., Crosby, S.D., Roberts, C.J., Grigsby,
P.W., Miner, J.H., Farr, A.G., and Kopan, R. (2008). Notch-deficient skin
induces a lethal systemic B-lymphoproliferative disorder by secreting TSLP,
a sentinel for epidermal integrity. PLoS Biol. 6, e123.
Demehri, S., Morimoto, M., Holtzman, M.J., and Kopan, R. (2009a). Skin-
derived TSLP triggers progression from epidermal-barrier defects to asthma.
PLoS Biol. 7, e1000067, doi:1000010.1001371/journal.pbio.1000067.
Demehri, S., Turkoz, A., and Kopan, R. (2009b). Epidermal Notch1 loss
promotes skin tumorigenesis by impacting the stromal microenvironment.
Cancer Cell 16, 55–66.
Di Piazza, M., Nowell, C.S., Koch, U., Durham, A.-D., and Radtke, F. (2012).
Loss of cutaneous TSLP-dependent immune responses skews the balance
of inflammation from tumor protective to tumor promoting. Cancer Cell 22,
this issue, 479–493.
Dumortier, A., Durham, A.-D., Di Piazza, M., Vauclair, S., Koch, U., Ferrand, G.,
Ferrero, I., Demehri, S., Song, L.L., Farr, A.G., et al. (2010). Atopic dermatitis-
like disease and associated lethal myeloproliferative disorder arise from loss
of Notch signaling in the murine skin. PLoS ONE 5, e9258.
Extance, A. (2010). Alzheimer’s failure raises questions about disease-
modifying strategies. Nat. Rev. Drug Discov. 9, 749–751.
Gandini, S., Lowenfels, A.B., Jaffee, E.M., Armstrong, T.D., and Maisonneuve,
P. (2005). Allergies and the risk of pancreatic cancer: a meta-analysis with
review of epidemiology and biological mechanisms. Cancer Epidemiol.
Biomarkers Prev. 14, 1908–1916.
Han, H., Xu, W., Headley, M.B., Jessup, H.K., Lee, K.S., Omori, M., Comeau,
M.R., Marshak-Rothstein, A., and Ziegler, S.F. (2012). Thymic stromal
lymphopoietin (TSLP)-mediated dermal inflammation aggravates experi-
mental asthma. Mucosal Immunol. 5, 342–351.
Hanahan, D., and Weinberg, R.A. (2000). The hallmarks of cancer. Cell 100,
57–70.
Hanahan, D., and Weinberg, R.A. (2011). Hallmarks of cancer: the next gener-
ation. Cell 144, 646–674.
He, R., Oyoshi, M.K., Garibyan, L., Kumar, L., Ziegler, S.F., and Geha, R.S.
(2008). TSLP acts on infiltrating effector T cells to drive allergic skin inflamma-
tion. Proc. Natl. Acad. Sci. USA 105, 11875–11880.
Hertzberg, L., Vendramini, E., Ganmore, I., Cazzaniga, G., Schmitz, M.,
Chalker, J., Shiloh, R., Iacobucci, I., Shochat, C., Zeligson, S., et al. (2010).
Down syndrome acute lymphoblastic leukemia, a highly heterogeneous
disease in which aberrant expression of CRLF2 is associated with mutatedancer Cell 22, 494–505, October 16, 2012 ª2012 Elsevier Inc. 503
Cancer Cell
TSLP Overexpression Protects from Skin CancerJAK2: a report from the International BFM Study Group. Blood 115, 1006–
1017.
Hwang, C.Y., Chen, Y.J., Lin, M.W., Chen, T.J., Chu, S.Y., Chen, C.C., Lee,
D.D., Chang, Y.T., Wang, W.J., and Liu, H.N. (2012). Cancer risk in patients
with allergic rhinitis, asthma and atopic dermatitis: a nationwide cohort study
in Taiwan. Int. J. Cancer 130, 1160–1167.
Jamali, I., Field, E.H., Fleming, A., and Cowdery, J.S. (1992). Kinetics of anti-
CD4-induced T helper cell depletion and inhibition of function. Activation of
T cells by the CD3 pathway inhibits anti-CD4-mediated T cell elimination
and down-regulation of cell surface CD4. J. Immunol. 148, 1613–1619.
Johansson, M., Denardo, D.G., and Coussens, L.M. (2008). Polarized immune
responses differentially regulate cancer development. Immunol. Rev. 222,
145–154.
Kessenbrock, K., Plaks, V., and Werb, Z. (2010). Matrix metalloproteinases:
regulators of the tumor microenvironment. Cell 141, 52–67.
Kopan, R., and Ilagan, M.X. (2009). The canonical Notch signaling pathway:
unfolding the activation mechanism. Cell 137, 216–233.
Lapins, J., Ye, W., Nyre´n, O., and Emtestam, L. (2001). Incidence of
cancer among patients with hidradenitis suppurativa. Arch. Dermatol. 137,
730–734.
Lee, E.B., Kim, K.W., Hong, J.Y., Jee, H.M., Sohn, M.H., and Kim, K.E. (2010).
Increased serum thymic stromal lymphopoietin in children with atopic derma-
titis. Pediatr. Allergy Immunol. 21, e457–e460.
Leonard, W.J. (2002). TSLP: finally in the limelight. Nat. Immunol. 3,
605–607.
Li, M., Hener, P., Zhang, Z., Kato, S., Metzger, D., and Chambon, P. (2006).
Topical vitamin D3 and low-calcemic analogs induce thymic stromal lympho-
poietin in mouse keratinocytes and trigger an atopic dermatitis. Proc. Natl.
Acad. Sci. USA 103, 11736–11741.
Li, T., Wen, H., Brayton, C., Laird, F.M., Ma, G., Peng, S., Placanica, L., Wu,
T.C., Crain, B.J., Price, D.L., et al. (2007). Moderate reduction of gamma-
secretase attenuates amyloid burden and limits mechanism-based liabilities.
J. Neurosci. 27, 10849–10859.
Mascia, F., Denning, M., Kopan, R., and Yuspa, S.H. (2012). The Black Box
Illuminated: Signals and Signaling. J. Invest. Dermatol. 132, 811–819.
Published online December 15, 2011. http://dx.doi.org/10.1038/jid.2011.406.
Morasso, M.I., and Tomic-Canic, M. (2005). Epidermal stem cells: the cradle
of epidermal determination, differentiation and wound healing. Biol. Cell 97,
173–183.
Murphy, W.J., Kumar, V., and Bennett, M. (1987). Acute rejection of murine
bone marrow allografts by natural killer cells and T cells. Differences in kinetics
and target antigens recognized. J. Exp. Med. 166, 1499–1509.
Nguyen, B.C., Lefort, K., Mandinova, A., Antonini, D., Devgan, V., Della Gatta,
G., Koster, M.I., Zhang, Z., Wang, J., Tommasi di Vignano, A., et al. (2006).
Cross-regulation between Notch and p63 in keratinocyte commitment to
differentiation. Genes Dev. 20, 1028–1042.
Nicolas, M., Wolfer, A., Raj, K., Kummer, J.A., Mill, P., van Noort, M., Hui, C.C.,
Clevers, H., Dotto, G.P., and Radtke, F. (2003). Notch1 functions as a tumor
suppressor in mouse skin. Nat. Genet. 33, 416–421.
Olkhanud, P.B., Rochman, Y., Bodogai, M., Malchinkhuu, E., Wejksza, K., Xu,
M., Gress, R.E., Hesdorffer, C., Leonard, W.J., and Biragyn, A. (2011). Thymic
stromal lymphopoietin is a key mediator of breast cancer progression.
J. Immunol. 186, 5656–5662.
Pan, Y., Lin, M.H., Tian, X., Cheng, H.T., Gridley, T., Shen, J., and Kopan, R.
(2004). gamma-secretase functions through Notch signaling to maintain skin
appendages but is not required for their patterning or initial morphogenesis.
Dev. Cell 7, 731–743.
Pedroza-Gonzalez, A., Xu, K., Wu, T.C., Aspord, C., Tindle, S., Marches, F.,
Gallegos, M., Burton, E.C., Savino, D., Hori, T., et al. (2011). Thymic stromal
lymphopoietin fosters human breast tumor growth by promoting type 2
inflammation. J. Exp. Med. 208, 479–490.
Peschon, J.J., Morrissey, P.J., Grabstein, K.H., Ramsdell, F.J., Maraskovsky,
E., Gliniak, B.C., Park, L.S., Ziegler, S.F., Williams, D.E., Ware, C.B., et al.504 Cancer Cell 22, 494–505, October 16, 2012 ª2012 Elsevier Inc.(1994). Early lymphocyte expansion is severely impaired in interleukin 7
receptor-deficient mice. J. Exp. Med. 180, 1955–1960.
Prizment, A.E., Folsom, A.R., Cerhan, J.R., Flood, A., Ross, J.A., and
Anderson, K.E. (2007). History of allergy and reduced incidence of colorectal
cancer, Iowa Women’s Health Study. Cancer Epidemiol. Biomarkers Prev.
16, 2357–2362.
Quigley, D.A., To,M.D., Pe´rez-Losada, J., Pelorosso, F.G., Mao, J.H., Nagase,
H., Ginzinger, D.G., and Balmain, A. (2009). Genetic architecture of mouse
skin inflammation and tumour susceptibility. Nature 458, 505–508.
Rangarajan, A., Syal, R., Selvarajah, S., Chakrabarti, O., Sarin, A., and Krishna,
S. (2001). Activated Notch1 signaling cooperates with papillomavirus
oncogenes in transformation and generates resistance to apoptosis on
matrix withdrawal through PKB/Akt. Virology 286, 23–30.
Rochman, I., Watanabe, N., Arima, K., Liu, Y.J., and Leonard, W.J. (2007).
Cutting edge: direct action of thymic stromal lymphopoietin on activated
human CD4+ T cells. J. Immunol. 178, 6720–6724.
Rochman, Y., and Leonard, W.J. (2008). The role of thymic stromal lympho-
poietin in CD8+ T cell homeostasis. J. Immunol. 181, 7699–7705.
Rochman, Y., Spolski, R., and Leonard, W.J. (2009). New insights into the
regulation of T cells by gamma(c) family cytokines. Nat. Rev. Immunol. 9,
480–490.
Rogers, H.W., and Unanue, E.R. (1993). Neutrophils are involved in acute,
nonspecific resistance to Listeria monocytogenes in mice. Infect. Immun.
61, 5090–5096.
Schmitt, C.A. (2011). Immunotherapy: TSLP fuels inflammation in breast and
pancreatic tumors. Nat. Rev. Clin. Oncol. 8, 254.
Schreiber, R.D., Old, L.J., and Smyth, M.J. (2011). Cancer immunoediting:
integrating immunity’s roles in cancer suppression and promotion. Science
331, 1565–1570.
Shankaran, V., Ikeda, H., Bruce, A.T., White, J.M., Swanson, P.E., Old, L.J.,
and Schreiber, R.D. (2001). IFNgamma and lymphocytes prevent primary
tumour development and shape tumour immunogenicity. Nature 410, 1107–
1111.
Shochat, C., Tal, N., Bandapalli, O.R., Palmi, C., Ganmore, I., Te Kronnie, G.,
Cario, G., Cazzaniga, G., Kulozik, A.E., Stanulla, M., et al. (2011). Gain-of-
function mutations in interleukin-7 receptor-{alpha} (IL7R) in childhood acute
lymphoblastic leukemias. J Exp Med.
Sneddon, J.B., and Werb, Z. (2007). Location, location, location: the cancer
stem cell niche. Cell Stem Cell 1, 607–611.
Tanaka, J., Watanabe, N., Kido, M., Saga, K., Akamatsu, T., Nishio, A., and
Chiba, T. (2009). Human TSLP and TLR3 ligands promote differentiation of
Th17 cells with a central memory phenotype under Th2-polarizing conditions.
Clin. Exp. Allergy 39, 89–100.
Vajdic, C.M., Falster, M.O., de Sanjose, S., Martı´nez-Maza, O., Becker, N.,
Bracci, P.M., Melbye, M., Smedby, K.E., Engels, E.A., Turner, J., et al.
(2009). Atopic disease and risk of non-Hodgkin lymphoma: an InterLymph
pooled analysis. Cancer Res. 69, 6482–6489.
Vesely, M.D., Kershaw, M.H., Schreiber, R.D., and Smyth, M.J. (2011).
Natural innate and adaptive immunity to cancer. Annu. Rev. Immunol. 29,
235–271.
Wang, B., Yang, W., Wen, W., Sun, J., Su, B., Liu, B., Ma, D., Lv, D., Wen, Y.,
Qu, T., et al. (2010). Gamma-secretase genemutations in familial acne inversa.
Science 330, 1065.
Wang, H., and Diepgen, T.L. (2005). Is atopy a protective or a risk factor for
cancer? A review of epidemiological studies. Allergy 60, 1098–1111.
Xia, X., Qian, S., Soriano, S., Wu, Y., Fletcher, A.M., Wang, X.J., Koo, E.H., Wu,
X., and Zheng, H. (2001). Loss of presenilin 1 is associated with enhanced
beta-catenin signaling and skin tumorigenesis. Proc. Natl. Acad. Sci. USA
98, 10863–10868.
Yuspa, S.H., D1ugosz, A.A., Cheng, C.K., Denning, M.F., Tennenbaum, T.,
Glick, A.B., and Weinberg, W.C. (1994). Role of oncogenes and tumor
suppressor genes in multistage carcinogenesis. J. Invest. Dermatol. 103 (5,
Suppl), 90S–95S.
Cancer Cell
TSLP Overexpression Protects from Skin CancerZhang, X., and Ren, R. (1998). Bcr-Abl efficiently induces a myeloproliferative
disease and production of excess interleukin-3 and granulocyte-macrophage
colony-stimulating factor in mice: a novel model for chronic myelogenous
leukemia. Blood 92, 3829–3840.
Zhang, Z., Hener, P., Frossard, N., Kato, S., Metzger, D., Li, M., and Chambon,
P. (2009). Thymic stromal lymphopoietin overproduced by keratinocytes inCmouse skin aggravates experimental asthma. Proc. Natl. Acad. Sci. USA
106, 1536–1541.
Ziegler, S.F. (2010). The role of thymic stromal lymphopoietin (TSLP) in allergic
disorders. Curr. Opin. Immunol. 22, 795–799.
Ziegler, S.F., and Artis, D. (2010). Sensing the outside world: TSLP regulates
barrier immunity. Nat. Immunol. 11, 289–293.ancer Cell 22, 494–505, October 16, 2012 ª2012 Elsevier Inc. 505
